The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

In a bid to deepen its manufacturing foothold in the U.S., Regeneron Pharmaceuticals in April pledged production and infrastructure investments surpassing $7 billion across North Carolina and its ...

After months of back-and-and forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

Regeneron Pharmaceuticals (REGN) has received approval from the European Commission for Libtayo (cemiplimab), to be used as an adjuvant treatment for adults with cutaneous squamous cell carcinoma ...

Regeneron is expanding its pharmaceutical production in New York, joining a wave of drug companies growing domestic manufacturing in the wake of President Donald Trump’s tariffs. The move is a boon to ...

As directors push for technology transformation, a new survey reveals a striking confidence gap in risk oversight—especially ...

Regeneron Pharmaceuticals received approval from the U.S. Food and Drug Administration for its eye treatment Eylea HD. The approval is for Eylea to treat macular edema following retinal vein occlusion ...

Thanks so much, everyone. It's funny. I had -- I was talking to an investor, and he -- it was his first time in London. He goes, it's not that crowded. And I think it's going to be okay, and I told ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, Canaccord Genuity analyst John Newman reaffirmed a Buy rating on ...